DRUG TRANSPORT IN THE LIVER - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 401

human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and
P-glycoprotein-mediated transport. Xenobiotica 35(7):737-753.
175. Nademanee K, Kannan R, Hendrickson J, Ookhtens M, Kay I, Singh BN. 1984.
Amiodarone-digoxin interaction: clinical significance, time course of development,
potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol
4(1):111-116.
176. Lambert C, Lamontagne D, Hottlet H, du Souich P. 1989. Amiodarone-digoxin
interaction in rats. A reduction in hepatic uptake. Drug Metab Dispos 17(6):704-708.
177. Kodawara T, Masuda S, Wakasugi H, Uwai Y, Futami T, Saito H, Abe T, Inu K. 2002.
Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone
in the rat liver. Pharm Res 19(6):738-743.
178. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T. 2005.
Possible involvement of organic anion transporter 2 on the interaction of theophylline
with erythromycin in the human liver. Drug Metab Dispos 33(5):619-622.
179. Bourdet DL, Pritchard JB, Thakker DR. 2005. Differential substrate and inhibitory
activities of ranitidine and famotidine toward human organic cation transporter 1
(hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp
Ther 315(3):1288-1297.
180. Angelin B, Arvidsson A, Dahlqvist R, Hedman A, Schenck-Gustafsson K. 1987.
Quinidine reduces biliary clearance of digoxin in man. Eur J Clin Invest 17(3):262-265.
181. Hedman A, Angelin B, Arvidsson A, Beck O, Dahlqvist R, Nilsson B, Olsson
M, Schenck-Gustafsson K. 1991. Digoxin-verapamil interaction: reduction of bil-
iary but not renal digoxin clearance in humans. Clin Pharmacol Ther 49(3):256-
262.
182. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE. 2004.
Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy
volunteers. Clin Pharmacol Ther 76(1):73-84.
183. Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, Marin JJ. 2003. Role of organic
anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-
maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 371(Pt 3):
897-905.
184. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ.
2002. The human bile salt export pump: characterization of substrate specificity and
identification of inhibitors. Gastroenterology 123(5):1649-1658.
185. Kostrubsky VE, Strom SC, Hanson J, Urda E, Rose K, Burliegh J, Zocharski P, Cai H,
Sinclair JF, Sahi J. 2003. Evaluation of hepatotoxic potential of drugs by inhibition of
bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci
76(1):220-228.
186. Sahi J, Sinz MW, Campbell S, Mireles R, Zheng X, Rose KA, Raeissi S, Hashim MF, Ye
Y, de Morais SM, et al. 2006. Metabolism and transporter-mediated drug-drug interac-
tions of the endothelin-A receptor antagonist CI-1034. Chem Biol Interact 159(2):156-
168.
187. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von
Richter O, Warzok R, Hachenberg T, et al. 2000. Induction of P-glycoprotein by rifampin
increases intestinal secretion of talinolol in human beings: a new type of drug/drug
interaction. Clin Pharmacol Ther 68(4):345-355.